462 related articles for article (PubMed ID: 24462818)
1. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Bowden NA
Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
[TBL] [Abstract][Full Text] [Related]
2. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
3. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.
Reed E
Cancer Treat Rev; 1998 Oct; 24(5):331-44. PubMed ID: 9861196
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
5. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L
Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622
[TBL] [Abstract][Full Text] [Related]
7. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
Boulikas T; Vougiouka M
Oncol Rep; 2004 Mar; 11(3):559-95. PubMed ID: 14767508
[TBL] [Abstract][Full Text] [Related]
8. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
Dabholkar M; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
J Clin Invest; 1994 Aug; 94(2):703-8. PubMed ID: 8040325
[TBL] [Abstract][Full Text] [Related]
9. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
10. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
13. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
[TBL] [Abstract][Full Text] [Related]
15. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
17. Excision repair cross complementing-group 1: gene expression and platinum resistance.
Altaha R; Liang X; Yu JJ; Reed E
Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
[TBL] [Abstract][Full Text] [Related]
18. Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells.
Chijiwa S; Masutani C; Hanaoka F; Iwai S; Kuraoka I
Carcinogenesis; 2010 Mar; 31(3):388-93. PubMed ID: 20015866
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds.
Tanaka S; Kobayashi I; Utsuki S; Oka H; Yasui Y; Fujii K
Oncol Rep; 2005 Nov; 14(5):1275-80. PubMed ID: 16211296
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]